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Abstract
Introduction: Vitamin D has been postulated to be involved in cancer prognosis. Thus far, only two studies
reported on its association with recurrence and survival after breast cancer diagnosis yielding inconsistent results.
Therefore, the aim of our study was to assess the effect of post-diagnostic serum 25-hydroxyvitamin D [25(OH)D]
concentrations on overall survival and distant disease-free survival.
Methods: We conducted a prospective cohort study in Germany including 1,295 incident postmenopausal breast
cancer patients aged 50-74 years. Patients were diagnosed between 2002 and 2005 and median follow-up was 5.8
years. Cox proportional hazards models were stratified by age at diagnosis and season of blood collection and
adjusted for other prognostic factors. Fractional polynomials were used to assess the true dose-response relation
for 25(OH)D.
Results: Lower concentrations of 25(OH)D were linearly associated with higher risk of death (hazard ratio (HR) =
1.08 per 10 nmol/L decrement; 95% confidence interval (CI), 1.00 to 1.17) and significantly higher risk of distant
recurrence (HR = 1.14 per 10 nmol/L decrement; 95%CI, 1.05 to 1.24). Compared with the highest tertile (≥ 55
nmol/L), patients within the lowest tertile (< 35 nmol/L) of 25(OH)D had a HR for overall survival of 1.55 (95%CI,
1.00 to 2.39) and a HR for distant disease-free survival of 2.09 (95%CI, 1.29 to 3.41). In addition, the association with
overall survival was found to be statistically significant only for 25(OH)D levels of blood samples collected before
start of chemotherapy but not for those of samples taken after start of chemotherapy (P for interaction = 0.06).
Conclusions: In conclusion, lower serum 25(OH)D concentrations may be associated with poorer overall survival
and distant disease-free survival in postmenopausal breast cancer patients.
Introduction
Vitamin D can be obtained from exposure to sunlight
and through diet and supplements. Low vitamin D levels
have been inconsistently associated with increased breast
cancer risk [1]. The anticarcinogenic potential of vita-
min D is attributed to the active or hormonal form of
vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)2D),
which is produced in the kidneys from the metabolite,
25-hydroxyvitamin D (25(OH)D) [2]. As 1,25(OH)2Di s
homeostatically tightly regulated, 25(OH)D is a better
indicator of vitamin D status from both sunlight expo-
sure and ingested vitamin D over longer periods [3].
It is currently unclear whether vitamin D affects breast
cancer survival, although some circumstantial evidence
exists. Several ecological studies in both the USA and
Europe have reported that breast cancer mortality rates
are inversely associated with total solar or ultraviolet B
irradiance [4-6]. Two studies in Norway and England
found that breast cancer mortality was lowest for can-
cers diagnosed in summer and autumn, the seasons
with the highest concentrations of 25(OH)D [7-9].
Lower serum 25(OH)D levels have also been associated
with more advanced stages of breast cancer. An observa-
tional study among Caucasian women showed that
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locally advanced or metastatic breast cancer than in
those with early-stage disease [10]. In a multi-ethnic
cohort of breast cancer survivors, women with localized
or regional breast cancer had lower serum 25(OH)D
levels than those with in situ disease [11].
To our knowledge, only two studies examined the
association between measured post-diagnostic circulat-
ing 25(OH)D concentrations and breast cancer recur-
rence and survival [12,13]. A prospective cohort study in
512 breast cancer patients reported that vitamin D defi-
ciency may be associated with increased risk of distant
recurrence and death [12]. However, this finding was
not confirmed in a recent nested case-control study
comparing 512 matched pairs of breast cancer patients
with and without recurrence [13]. Thus, we examined
post-diagnostic serum concentrations of 25(OH)D in
relation to overall and distant disease-free survival in a
large prospective cohort of 1,295 postmenopausal breast
cancer patients.
Materials and methods
Study population
Patients were recruited from 2002 to 2005 within a large
population-based case-control study on breast cancer in
two regions in Germany (MARIE study, Mamma Carci-
noma Risk factor Investigation) [14], and a follow up was
performed up to the end of 2009. Individuals in this ana-
lysis were patients with histologically confirmed primary
invasive (stage I to IV) or in situ breast cancer diagnosed
between 1 August 2002 and 31 July 2005 in the Rhein-
Neckar-Karlsruhe region. Patients were identified
through frequent monitoring of hospital admissions, sur-
gery schedules and pathology records. Patients were aged
between 50 and 74 years and postmenopausal (defined as
last menstrual bleeding at least 12 months before the
date of diagnosis, a bilateral oophorectomy, cessation of
menses due to radiation or chemotherapy, > 55 years
with unclear menopausal status due to hysterectomy or
hormone use). Post-diagnostic serum samples were avail-
able for 1,385 patients. After exclusion of patients with
previous cancer (other than basal or squamous skin can-
cers or in situ cancers) or missing information on pre-
vious cancer (n = 90), our final study population
consisted of 1,295 postmenopausal breast cancer patients.
This study was approved by the ethics committees of
both the University of Heidelberg and the University of
Hamburg and conducted in accordance with the
Declaration of Helsinki. All study participants provided
informed consent.
Exposure assessment
Serum was collected after cancer diagnosis and stored in
aliquots at -80°C until measurement. Samples were
previously analyzed in a single batch between November
2006 and January 2007 [15]. For quantification of 25
(OH)D in serum, the OCTEIA 25(OH)D enzyme immu-
noassay (Immunodiagnostic Systems Limited, Boldon,
UK) was used. The intra-assay and inter-assay coeffi-
cient of variation were 3.4% and 7.6%, respectively.
Clinical and pathological characteristics were
abstracted from hospital and pathology records. All
patients were interviewed at recruitment (2002 to 2005)
by trained personnel to obtain information on sociode-
mographic factors, anthropometric measures, lifetime
hormone replacement therapy (HRT) exposure, and
other potential breast cancer risk factors.
Outcome assessment
Vital status of participants was determined through
population registries up to the end of 2009, and all
deaths were verified by death certificates. Recurrences of
the primary breast cancer or second cancers were iden-
tified during a telephone interview conducted from May
to September 2009. Further, for deceased participants
and those not participating in the telephone interview,
medical records were checked or treating physicians
were contacted. All recurrences or second cancers were
verified by clinical records or through records from
treating physicians. Primary outcomes were overall sur-
vival and distant disease-free survival (including distant
recurrence, death, second primary invasive non-breast
cancer), secondary outcomes were breast cancer-specific
survival and recurrence-free survival (including ipsilat-
eral/local/regional invasive recurrence, distant recur-
rence, death) [16]. Analyses for distant disease-free
survival and recurrence-free survival were restricted to
participants with in situ breast cancer or stage I to IIIa
disease (n = 1,088). Participants were censored at date
of last contact or 31 December 2009, whichever came
first.
Statistical analyses
Cox proportional hazards models were used to examine
the association of serum 25(OH)D with overall survival
and distant disease-free survival as primary endpoints,
and breast cancer-specific survival and recurrence-free
survival as secondary endpoints. Hazard ratios (HR) and
95% confidence intervals (CIs) were calculated using 25
(OH)D concentration both as continuous (per 10 nmol/
L decrement) and as categorical variable divided into
three categories (< 35 nmol/L, 35 to 55 nmol/L, ≥ 55
nmol/L), closely corresponding to the classification into
tertiles. The highest exposure category was defined as
the reference category. Follow-up time was used as the
time variable, and calculated as the time between the
date of diagnosis and the date of event or censoring. All
analyses were stratified by age at diagnosis (in one-year
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March, April to June, July to September, October to
December). Analyses were adjusted for the traditional
prognostic variables, that is, tumor size (in situ,n e o a d -
juvant chemotherapy, ≤ 2 cm, 2 to 5 cm, > 5 cm, growth
in chest wall/skin), nodal status (in situ, neoadjuvant
chemotherapy, 0, 1 to 3, 4 to 9, ≥ 10), metastasis (in
situ, yes, no), tumor grade (in situ, neoadjuvant che-
motherapy, low + moderate, high), and joint estrogen
receptor (ER)/progesterone receptor (PR) status (in situ,
neoadjuvant chemotherapy, ER
+PR
+,E R
+PR
-/ER
-PR
+,
ER
-PR
-). In addition, analyses were adjusted for variables
that were statistically significant (< 0.05) when tested in
the model, that is, self-reported prevalent diabetes (yes,
no) and mode of detection (physician-detected by rou-
tine investigation/mammography/ultrasound, self-
detected by palpation/secretion/pain). Other potentially
confounding variables were not statistically significant
and did not change the risk estimates by 10% or more
when tested in the model and were therefore not
included in the final model, that is, human epidermal
growth factor receptor 2 (HER2) status, type of surgery,
chemotherapy, radiotherapy, hormonal therapy, HRT
use, body mass index (BMI) at time of recruitment, lei-
sure time physical activity since age 50 years, cardiovas-
cular disease, and time between diagnosis and blood
collection. Tests for linear trend with log HR were per-
formed using 25(OH)D concentration as a continuous
variable. We used the method of fractional polynomials
to further examine dose-response relation and non-line-
arity of the log HR for 25(OH)D concentrations [17].
The continuous 25(OH)D variable was entered into the
multivariate cox proportional hazards model via a set of
defined transformations (x
-2, x
-1, x
-0.5, x
0.5, x
2, x
3 and log
(x)), allowing a maximum of two terms (including the
untransformed variable) in the model. The function that
best fitted the data was selected on the basis of the -2
log likelihood of the respective model.
We performed sensitivity analyses by time between
diagnosis and blood collection and by time of blood col-
lection relative to start of chemotherapy (blood collec-
tion before start of chemotherapy or non-chemotherapy
vs blood collection after start of chemotherapy).
We performed stratified analyses to examine whether
the associations between 25(OH)D and survival varied
by BMI at time of recruitment (less than vs median or
above kg/m
2), leisure time physical activity since age 50
(less than vs median or above median metabolic equiva-
lent (MET)-h/wk), HRT use (never/past vs current), and
ER status (ER
+ vs ER
-). We then included interaction
terms of the continuous 25(OH)D concentration vari-
able and the variables of interest in the fully adjusted
model and evaluated statistical significance with the
likelihood ratio test.
All tests were two-sided and considered to be statisti-
cally significant if P value was less than 0.05. All statisti-
cal analyses were performed using SAS software 9.2
(SAS Institute, Cary, NC, USA).
Results
Mean (standard deviation) age at diagnosis was 63.4 ±
5.5 years. Serum samples were drawn a median of 83
days after diagnosis (range 2 to 1,112 days), and the
median 25(OH)D level was 44.9 nmol/L (range 9.7 to
240.3 nmol/L).
Baseline characteristics according to tertiles of serum
25(OH)D are shown in Table 1. Participants with lower
25(OH)D levels were diagnosed at a somewhat older
age, had a shorter time interval between diagnosis and
blood collection, a higher BMI at time of recruitment,
and less leisure time physical activity since age 50 years
compared with participants with higher 25(OH)D levels.
Participants in the lowest tertile of serum 25(OH)D
were more likely to have their blood collected in winter.
Further, they had a higher proportion of tumors with a
larger tumor size, more lymph node involvement,
metastases, and a higher tumor grade, and a lower pro-
portion of ER
-PR
- tumors. They were also more likely to
be treated with chemotherapy, not to use HRT, to have
diabetes or cardiovascular disease, and to have a self-
detected tumor. No clear differences in radiotherapy or
tamoxifen/aromatase inhibitor use by tertiles of serum
25(OH)D were observed.
Overall, median follow-up time was 5.8 years (range
0.2 to 7.7 years) and 183 deaths occurred, 137 due to
breast cancer. Other causes of death were other cancers
(n = 16), cardiovascular disease (n = 18), and other
causes (n = 12). Of the patients with in situ breast can-
cer or stage I to IIIa disease, 137 women experienced an
event related to distant disease-free survival and 145
women experienced an event related to recurrence-free
survival.
We assessed the association of post-diagnostic serum
25(OH)D with survival. Results for overall survival and
breast cancer-specific survival and results for distant dis-
ease-free survival and recurrence-free survival were
similar: overall survival and distant disease-free survival
results are presented here (Table 2). A trend towards
increased risk of death was seen, with an adjusted HR of
1.08 (95% CI, 1.00 to 1.17; P for trend = 0.07) per 10
nmol/L decrement in 25(OH)D. The adjusted HR for
the highest compared with the lowest tertile of 25(OH)
D was 1.55 (95% CI, 1.00 to 2.39). Restriction to partici-
pants with stage I to IIIa disease provided similar results
(per 10 nmol/L decrement: HR = 1.11; 95% CI, 0.99 to
1.23; P for trend = 0.08, lowest vs highest tertile: HR =
1.67; 95% CI, 0.91 to 3.06; data not shown). The
adjusted HR for risk of distant disease was significantly
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Page 3 of 9Table 1 Baseline characteristics of study cohort according to tertiles of serum 25(OH)D (n = 1,295)
Serum 25(OH)D
Characteristic < 35 nmol/L 35-55 nmol/L ≥ 55 nmol/L
Number of patients 432 407 456
Age at diagnosis (years), mean ± SD 64.0 ± 5.7 63.7 ± 5.4 62.5 ± 5.4
25(OH)D concentration (nmol/L), median 25.7 44.4 71.3
Follow-up time (years), median 5.6 5.9 6.0
Time between diagnosis and blood collection (days), median 82 63 130
BMI at recruitment (kg/m
2), mean ± SD 27.7 ± 4.9 26.6 ± 4.4 25.5 ± 4.1
Leisure time physical activity since age 50 (met-hr/wk), mean ± SD 37.3 ± 30.0 43.5 ± 33.0 49.5 ± 36.4
Season of blood draw, %
Jan-Mar 37.5 16.7 13.6
Apr-Jun 22.0 24.8 16.0
Jul-Sept 13.0 29.5 43.6
Oct-Dec 27.5 29.0 26.8
Tumor size, %
In situ 3.9 4.9 8.3
≤ 2c m 44.4 51.8 51.1
>2 -≤ 5 cm 32.9 32.4 32.2
>5c m 5.6 2.2 2.6
Growth into chest wall/skin 5.6 2.0 1.6
Neoadjuvant CT 7.4 6.1 4.2
Missing 0.2 0.5 0.0
Nodal status, %*
0 54.4 58.2 59.6
1-3 19.2 19.7 19.7
4-9 6.7 6.6 4.0
≥ 10 7.6 3.7 4.2
Missing 0.7 0.7 0.0
Metastases, %
In situ 3.9 4.9 8.3
No 89.1 89.7 88.8
Yes 5.6 4.9 2.2
Missing 1.4 0.5 0.7
Tumor grade, %*
Low + moderate 61.1 65.1 64.5
High 27.3 23.3 22.8
Missing 0.2 0.5 0.2
ERPR, %*
ER
+PR
+ 55.3 55.0 50.9
ER
+PR
-/ER
-PR
+ 19.2 15.7 20.8
ER
-PR
- 14.1 17.4 15.8
Missing 0.0 0.7 0.0
Chemotherapy, %
No 49.1 52.1 58.8
Yes 48.8 47.6 41.0
Missing 2.1 0.3 0.2
Radiotherapy, %
No 27.8 17.9 25.4
Yes 72.0 82.1 74.4
Missing 0.2 0.0 0.2
Tamoxifen/aromatase inhibitor use, %
No 14.8 18.9 19.3
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1.05 to 1.24; P for trend = 0.006, lowest vs highest ter-
tile: HR = 2.09; 95% CI, 1.29 to 3.41). We further exam-
ined the shape of the association using fractional
polynomials and found a linear association between the
log HR and the 25(OH)D concentration for both overall
survival and distant disease-free survival (data not
shown).
To evaluate whether the association between serum
25(OH)D and survival depends on the time interval
between cancer diagnosis and blood collection, we
restricted our analyses to a time interval of 2, 1, and
0.5 years (Table 3). The HRs for death were some-
what larger with a shorter period between cancer
diagnosis and blood collection. However, there was
no significant difference for risk of death and for dis-
tant disease by time of blood collection after cancer
diagnosis.
Given that serum levels of 25(OH)D could be affected
by chemotherapy, we investigated whether the associa-
tion with survival differed for participants that did not
r e c e i v ec h e m o t h e r a p yb e f o r eb l o o dc o l l e c t i o na n dp a r t i -
cipants with blood collection after start of chemotherapy
(Table 4). The association with risk of death remained
significant only for participants that did not receive che-
motherapy before blood collection (per 10 nmol/L
decrement: HR = 1.15; 95% CI, 1.03 to 1.27; P for trend
= 0.02) whereas no association was found for partici-
pants with blood collection after start of chemotherapy
(P for interaction = 0.06). However, for risk of distant
Table 2 Hazard ratios of overall mortality and distant disease according to tertiles of serum 25(OH)D
Serum 25(OH)D
Continuous Categorized
per 10 nmol/L decrement < 35 nmol/L 35-55 nmol/L ≥ 55 nmol/L
Outcome No.
(events)
HR 95% CI Ptrend
a No.
(events)
HR 95% CI No.
(events)
HR 95% CI No.
(events)
HR 95% CI
Overall mortality
Crude†
b 1,295 (183) 1.11 1.03 to 1.18 0.009 432 (87) 1.96 1.32 to 2.90 407 (46) 0.94 0.62 to 1.44 456 (50) 1.00 -
Multivariate‡
c 1,265 (174) 1.08 1.00 to 1.17 0.07 422 (82) 1.55 1.00 to 2.39 397 (44) 0.72 0.45 to 1.17 446 (48) 1.00 -
Distant disease
Crude
b 1,088 (137) 1.12 1.03 to 1.21 0.01 341 (64) 2.09 1.31 to 3.30 347 (37) 1.19 0.73 to 1.93 400 (36) 1.00 -
Multivariate
c 1,074 (135) 1.14 1.05 to 1.24 0.006 338 (63) 2.09 1.29 to 3.41 342 (37) 1.16 0.70 to 1.94 394 (35) 1.00 -
25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; HR, hazard ratio.
a Calculated by using serum 25(OH)D as a continuous variable.
b Stratified by age at diagnosis and season.
c Stratified by age at diagnosis and season, adjusted for tumor size, nodal status, metastases, tumor grade, estrogen/progesterone receptor status, diabetes,
mode of detection; due to missing covariate values, 30 observations were not included in the multivariate model.
Table 1 Baseline characteristics of study cohort according to tertiles of serum 25(OH)D (n = 1,295) (Continued)
Yes 79.9 77.2 76.3
Missing 5.3 3.9 4.4
Hormone replacement therapy, %
No 71.1 57.7 48.9
Yes 27.8 41.5 50.0
Missing 1.1 0.7 1.1
Diabetes, %
No 87.0 89.7 91.9
Yes 13.0 10.3 7.9
Missing 0.0 0.0 0.2
Cardiovascular disease, %
No 41.0 48.2 51.8
Yes 59.0 51.8 48.2
Mode of detection, %
Self-detected by palpation/secretion/pain 65.3 56.3 53.5
Physician-detected by routine investigation/mammography/ultrasound 34.5 43.5 45.4
Missing 0.2 0.2 1.1
25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; CT, chemotherapy; ERPR, estrogen receptor/progesterone receptor; SD, standard deviation.
* Includes a separate category for in situ and neoadjuvant CT.
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action = 0.49).
We further examined the association for serum 25
(OH)D across strata of other potential predictors of can-
cer recurrence and mortality (Table 5). Associations
tended to be stronger among participants that had a
higher BMI at time of recruitment, higher leisure time
physical activity since age 50 years, and were never or
past users of HRT. However, statistical power was
diminished, and none of the P-values for interaction
were statistically significant.
Discussion
To our knowledge, this is the largest cohort study to
date investigating the association between vitamin D
and breast cancer survival using 25(OH)D as a reliable
biomarker and direct indicator of bodily vitamin D
stores. We found that postmenopausal breast cancer
patients with lower post-diagnostic serum 25(OH)D
levels were at a statistically significant increased risk of
distant recurrence. An association for risk of death was
statistically significant only for participants that did not
receive chemotherapy before blood collection.
Table 4 Hazard ratios
a according to tertiles of serum 25(OH)D and chemotherapy
Serum 25(OH)D
Continuous Categorized
per 10 nmol/L decrement < 35 nmol/L 35-55 nmol/L ≥ 55 nmol/L
Outcome No.
(events)
HR 95% CI Ptrend
b No.
(events)
HR 95% CI No.
(events)
HR 95% CI No.
(events)
HR 95% CI
Overall mortality
All 1,265 (174) 1.08 1.00 to 1.17 0.07 422 (82) 1.55 1.00 to 2.39 397 (44) 0.72 0.45 to 1.17 446 (48) 1.00 -
No/before CT
c 911 (99) 1.15 1.03 to 1.27 0.02 292 (51) 2.17 1.18 to 3.99 276 (20) 1.00 0.51 to 1.96 343 (28) 1.00 -
After CT
d 339 (71) 0.91 0.75 to 1.08 0.27 121 (29) 0.82 0.35 to 1.95 117 (22) 0.59 0.24 to 1.44 101 (20) 1.00 -
Distant disease
All 1,074 (135) 1.14 1.05 to 1.24 0.006 338 (63) 2.09 1.29 to 3.41 342 (37) 1.16 0.70 to 1.94 394 (35) 1.00 -
No/before CT
c 844 (103) 1.17 1.06 to 1.29 0.005 259 (50) 2.41 1.37 to 4.22 263 (26) 1.07 0.59 to 1.94 322 (27) 1.00 -
After CT
d 221 (32) 1.12 0.85 to 1.39 0.41 73 (13) 1.79 0.35 to 9.00 78 (11) 0.84 0.14 to 4.97 70 (8) 1.00 -
Note: 18 and 9 participants, respectively, had missing data on chemotherapy and were excluded from the stratified analyses.
25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; CT, chemotherapy; HR, hazard ratio.
a Stratified by age at diagnosis and season, adjusted for tumor size, nodal status, metastases, tumor grade, estrogen/progesterone receptor status, diabetes,
mode of detection
b Calculated by using serum 25(OH)D as a continuous variable.
c No chemotherapy or blood collection before start chemotherapy.
d Blood collection after start chemotherapy.
Pinteraction = 0.06 and 0.49 for overall mortality and distant disease, respectively.
Table 3 Hazard ratios
a according to tertiles of serum 25(OH)D and time between diagnosis and blood collection
Serum 25(OH)D
Continuous Categorized
per 10 nmol/L decrement < 35 nmol/L 35-55 nmol/L ≥ 55 nmol/L
Outcome No.
(events)
HR 95% CI Ptrend
b No.
(events)
HR 95% CI No.
(events)
HR 95% CI No.
(events)
HR 95% CI
Overall mortality
All 1,265 (174) 1.08 1.00 to 1.17 0.07 422 (82) 1.55 1.00 to 2.39 397 (44) 0.72 0.45 to 1.17 446 (48) 1.00 -
< 2 years 1,249 (172) 1.09 1.00 to 1.17 0.05 418 (82) 1.57 1.01 to 2.43 394 (44) 0.75 0.46 to 1.22 437 (46) 1.00 -
< 1 year 1,093 (151) 1.13 1.03 to 1.22 0.02 375 (77) 1.81 1.11 to 2.94 353 (39) 0.82 0.48 to 1.42 365 (35) 1.00 -
< 0.5 year 807 (119) 1.15 1.03 to 1.26 0.02 277 (63) 2.19 1.21 to 3.97 275 (33) 0.96 0.50 to 1.83 255 (23) 1.00 -
Distant disease
All 1,074 (135) 1.14 1.05 to 1.24 0.006 338 (63) 2.09 1.29 to 3.41 342 (37) 1.16 0.70 to 1.94 394 (35) 1.00 -
< 2 years 1,059 (133) 1.15 1.05 to 1.25 0.005 335 (63) 2.11 1.30 to 3.45 339 (37) 1.17 0.70 to 1.95 385 (33) 1.00 -
< 1 year 925 (119) 1.15 1.05 to 1.26 0.007 298 (59) 2.24 1.32 to 3.79 302 (32) 1.28 0.74 to 2.22 325 (28) 1.00 -
< 0.5 year 685 (95) 1.13 1.01 to 1.25 0.05 219 (48) 2.16 1.18 to 3.98 235 (25) 1.12 0.60 to 2.10 231 (22) 1.00 -
25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; HR, hazard ratio.
a Stratified by age at diagnosis and season, adjusted for tumor size, nodal status, metastases, tumor grade, estrogen/progesterone receptor status, diabetes,
mode of detection.
b Calculated by using serum 25(OH)D as a continuous variable.
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in cancer survival exists [6], but the association between
measured serum 25(OH)D concentrations and breast
cancer recurrence and survival has only been investi-
gated in two previous studies [12,13]. These studies
were conducted in Canada [12] and the USA [13] and
levels of 25(OH)D were relatively high compared with
those in our study, probably due to milk fortification
with vitamin D and higher use of supplements contain-
ing vitamin D. One study in 512 breast cancer patients
collected blood on average 58 days after diagnosis and
before initiation of systemic therapy [12]. In this study,
serum 25(OH)D concentrations less than 50 nmol/L
compared with more than 72 nmol/L were associated
with an increased risk of distant recurrence and death.
Associations were attenuated after multivariate adjust-
ment for tumor-related factors. In a matched case-con-
trol analysis in 512 pairs of breast cancer patients with
and without a recurrence, blood was collected approxi-
mately two years after diagnosis and after completion of
treatment for breast cancer [13]. When comparing
serum 25(OH)D concentrations less than 25 nmol/L to
75 nmol/L or above, no association with breast cancer
recurrence was observed.
The relevant time period during which 25(OH)D
levels may affect breast cancer recurrence or survival is
currently unknown. The results of our study together
with findings of the two previous studies could indicate
that serum 25(OH)D concentrations measured shortly
after diagnosis are associated with breast cancer recur-
rence and survival. However, the null association for
serum 25(OH)D measured at least two years after diag-
n o s i s[ 1 3 ]c o u l dn o tb ea s s e s s e di no u rs t u d yd u et o
small numbers, and deserves further investigation.
Our results of a significantly poorer survival associated
with lower 25(OH)D levels were restricted to partici-
pants not receiving chemotherapy before blood collec-
tion, which is comparable with those of the Canadian
study [12]. Adjuvant chemotherapy may affect 25(OH)D
levels, either directly or indi r e c t l yb yi n d u c i n gn a u s e a
and subsequently reducing dietary vitamin D intake or
by decreasing physical activity or sun exposure. One
[18] out of three studies [18-20] showed an effect of
chemotherapeutic treatment on 25(OH)D levels in
breast cancer patients, but study sizes were small (n =
20, n =9 ,a n dn = 103, respectively) and in one study
[20] vitamin D supplementation was used. In our study,
a larger proportion of women in the lowest compared
with the highest tertile of 25(OH)D levels received che-
motherapy, and 25(OH)D levels were somewhat lower
in participants with blood collected after start of che-
motherapy compared with those with blood collected
before start of chemotherapy or not receiving che-
motherapy (data not shown). Examination of the effect
of chemotherapy on 25(OH)D levels in more detail
would be of great interest.
Serum 25(OH)D levels have been associated with
tumor-related and lifestyle-related factors, and the
Table 5 Multivariate-adjusted
a stratified analyses of overall mortality according to tertiles of serum 25(OH)D
Serum 25(OH)D
Continuous Categorical
per 10 nmol/L decrement < 35 nmol/L 35-55 nmol/L ≥ 55 nmol/L
Variable Total no. HR 95%CI Ptrend
b HR 95%CI HR 95%CI Pinteraction
c
BMI, kg/m
2d 0.74
< 26 382 1.05 0.66 to 1.44 0.81 0.64 0.08 to 5.00 0.02 0.00 to 2.06 Referent
≥ 26 393 1.15 0.94 to 1.36 0.20 2.57 0.88 to 7.54 0.60 0.19 to 1.92 Referent
Leisure time physical activity, MET-h/wk 0.49
< 37 631 1.04 0.92 to 1.17 0.50 1.19 0.62 to 2.29 0.63 0.30 to 1.32 Referent
≥ 37 629 1.19 1.03 to 1.35 0.03 1.90 0.85 to 4.24 0.57 0.22 to 1.48 Referent
HRT use 0.40
Never, past 746 1.13 1.01 to 1.25 0.04 1.89 1.09 to 3.26 0.61 0.31 to 1.19 Referent
Current 506 1.03 0.86 to 1.21 0.73 0.89 0.26 to 3.05 1.17 0.46 to 2.98 Referent
ER status 0.78
ER
+ 903 1.08 0.97 to 1.19 0.17 1.70 0.95 to 3.05 0.72 0.39 to 1.35 Referent
ER
- 276 1.09 0.84 to 1.35 0.50 1.48 0.38 to 5.76 0.81 0.21 to 3.09 Referent
25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; HRT, hormone replacement therapy.
a Stratified by age at diagnosis and season, adjusted for tumor size, nodal status, metastases, tumor grade, estrogen/progesterone receptor status, diabetes,
mode of detection.
b Calculated by using serum 25(OH)D as a continuous variable.
c Calculated by entering in the model the cross-product of 25(OH)D as a continuous variable with the covariate as a binary variable. Cutpoints for BMI and leisure
time physical activity were based on median values.
d Participants with blood collection after start of chemotherapy and with BMI obtained more than one month before/after blood collection were excluded from
this analysis stratified by BMI.
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Page 7 of 9observed association in our study may not be due to
an independent effect of 25(OH)D but instead be
reflective of another factor related to 25(OH)D. The
current study and several other studies [10-13] showed
that lower 25(OH)D levels are related to more
advanced tumor stage at diagnosis. Further, vitamin D
metabolism is disrupted in breast cancer progression
[21]. Our analyses were adjusted for all relevant tumor
characteristics, but we cannot exclude potential resi-
dual confounding. Lower serum levels of 25(OH)D
have also been associated with higher BMI and lower
physical activity [22], which was confirmed by our
study. However, after restriction to patients with BMI
reported within one month of blood collection and
exclusion of patients with blood collection after start
of chemotherapy, adjustment for BMI did not substan-
tially change the risk estimates. We had no data on
physical activity at time of blood collection, however,
adjustment for leisure time physical activity since age
50 years did not affect the risk estimates. Thus, the
observed association of serum 25(OH)D with survival
after breast cancer appeared to be independent of BMI
and physical activity although we cannot exclude con-
founding by potential changes in these factors during
follow up. However, stratification of our analyses by
tumor stage provided similar results (data not shown),
indicating that 25(OH)D levels are associated with
prognosis independent of disease severity or overall
well being.
We did not observe effect modification by other
potential predictors of breast cancer recurrence and
mortality, such as BMI, physical activity, HRT use, and
ER status. However, our study may not have had suffi-
cient statistical power to detect moderate effects. Poten-
tial effect modification by BMI is of particular interest,
and has been observed in a previous study on prediag-
nostic 25(OH)D levels in colorectal cancer survivors
[ 2 3 ] .Ap o s s i b l ee x p l a n a t i o nm a yb et h a tb e s i d e si t s
anticarcinogenic properties, 25(OH)D has anti-inflam-
matory properties that may have an additional beneficial
effect on the inflammatory state that is characteristic for
obese individuals [23]. However, further investigation in
larger studies is warranted.
Strengths of our study are the restriction to postme-
nopausal women, the population-based design, complete
follow up, and detailed data on many potential confoun-
ders (tumor characteristics, therapy, lifestyle factors).
However, similar to other observational studies, we only
had a single measurement of 25(OH)D, which may not
be reflective of long-term 25(OH)D concentrations, lim-
ited power to detect interactions with other vitamin D-
related lifestyle factors, and we cannot exclude residual
or uncontrolled confounding.
Conclusions
The results of our study suggest that lower serum 25
(OH)D concentrations after a diagnosis with postmeno-
pausal breast cancer are associated with poorer overall
survival and distant disease-free survival. The association
with overall survival might be restricted to patients not
receiving chemotherapy before blood collection. The
relevant time frame of and the effect of chemotherapy
on serum 25(OH)D measurements in breast cancer sur-
vival studies deserves further investigation.
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